ReviewSage open aging
An Update of the Treatment Landscape for Alzheimer's Disease: From Symptomatic Treatments to the Emergence of Amyloid-Targeting Therapies.
Review in Sage open aging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- T1 mapping in Alzheimer's disease: a quantitative MRI study with amyloid-PET correlation.European radiology experimental · 2026Article
- Review
- FSH Signaling in Osteoporosis and Alzheimer's Disease.Current osteoporosis reports · 2026Review
- Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system.Frontiers in pharmacology · 2026Article
- Alzheimer's Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations.Clinical interventions in aging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several approved Alzheimer's disease (AD) treatments help manage its associated cognitive symptoms (e.g., donepezil and memantine) or non-cognitive symptoms. However, disease-modifying AD therapies have recently emerged. These treatments aim to slow disease progression by targeting the pathology associated with progressive neurodegeneration. Specifically, two amyloid-targeting therapies (ATTs) are currently approved and available for use in the United States: the monoclonal antibodies donanemab (Kisunla™) and lecanemab (Leqembi
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.